Goldman Sachs’s Entrada Therapeutics TRDA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $565K | Sell |
84,150
-8,390
| -9% | -$56.4K | ﹤0.01% | 4195 |
|
|
2025
Q1 | $837K | Sell |
92,540
-192,732
| -68% | -$1.74M | ﹤0.01% | 3932 |
|
|
2024
Q4 | $4.93M | Buy |
285,272
+200,806
| +238% | +$3.47M | ﹤0.01% | 2875 |
|
|
2024
Q3 | $1.35M | Buy |
84,466
+51,164
| +154% | +$818K | ﹤0.01% | 3595 |
|
|
2024
Q2 | $475K | Buy |
33,302
+15,979
| +92% | +$228K | ﹤0.01% | 3986 |
|
|
2024
Q1 | $245K | Sell |
17,323
-741
| -4% | -$10.5K | ﹤0.01% | 4267 |
|
|
2023
Q4 | $273K | Buy |
18,064
+5,260
| +41% | +$79.4K | ﹤0.01% | 4225 |
|
|
2023
Q3 | $202K | Sell |
12,804
-8,532
| -40% | -$135K | ﹤0.01% | 4254 |
|
|
2023
Q2 | $323K | Sell |
21,336
-25,840
| -55% | -$391K | ﹤0.01% | 4200 |
|
|
2023
Q1 | $684K | Sell |
47,176
-354,863
| -88% | -$5.15M | ﹤0.01% | 3905 |
|
|
2022
Q4 | $5.44M | Sell |
402,039
-47,954
| -11% | -$648K | ﹤0.01% | 2557 |
|
|
2022
Q3 | $7.09M | Buy |
449,993
+4,307
| +1% | +$67.9K | ﹤0.01% | 2391 |
|
|
2022
Q2 | $5.43M | Buy |
445,686
+231
| +0.1% | +$2.81K | ﹤0.01% | 2592 |
|
|
2022
Q1 | $4.18M | Hold |
445,455
| – | – | ﹤0.01% | 2933 |
|
|
2021
Q4 | $7.63M | Buy |
+445,455
| New | +$7.63M | ﹤0.01% | 2477 |
|